Evidence map›Paper›PMID 40410905›Full record

ArticleOrphanet journal of rare diseases2025

Lipidomic profiling of the cerebrospinal fluid in moyamoya angiopathy patients.

Antonella Potenza, Gemma Gorla, Tatiana Carrozzini, Giuliana Pollaci, Michele Dei Cas, Francesco Acerbi, Ignazio G Vetrano, Paolo Ferroli, Isabella Canavero, Rita Paroni and 3 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lipid metabolism in moyamoya disease: Emerging evidence, vascular remodeling, and therapeutic implications.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Antonella Potenza *Laboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Gemma Gorla *Laboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Tatiana CarrozziniLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Giuliana PollaciLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Michele Dei CasClinical Biochemistry and Mass Spectrometry Lab, Department of Health Sciences, Università degli Studi di Milano, 20132, Milan, Italy.
Francesco AcerbiNeurosurgical Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Ignazio G VetranoNeurosurgical Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Paolo FerroliNeurosurgical Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Isabella CanaveroLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Rita ParoniClinical Biochemistry and Mass Spectrometry Lab, Department of Health Sciences, Università degli Studi di Milano, 20132, Milan, Italy.
Nicola RifinoLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Anna BersanoLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy.
Laura GattiLaboratory of Neurobiology and UCV, Neurology IX Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133, Milan, Italy. laura.gatti@istituto-besta.it.ORCID http://orcid.org/0000-0001-6751-5031

Funding

Ministero della Salute PNRR-MR1-2022-12376618Ministero della Salute RCR-2021-23671214Ministero della Salute RF-2019-12369247Ministero della Salute RRC 2018-2023
6 · The paper itself

Abstract

backgroundMoyamoya angiopathy (MA) is a rare cerebrovascular disorder which can occur in both children and young adults, characterized by progressive occlusion of the intracranial carotid arteries, leading patients to ischemic and haemorrhagic strokes. Despite decades of research, the mechanisms underlying MA remain poorly clarified and current gaps in the understanding of pathogenesis have hampered the development of suitable preventive strategies and therapeutic options. Moreover, clinically approved biomarkers for MA patients' stratification are missing. The unknown pathophysiology and the lack of reliable biomarkers prompted us to investigate cerebrospinal fluid (CSF) lipidome through state-of-the-art lipidomics.

methodsIntraoperative CSF from a subgroup of MA patients in comparison to age/sex matched controls (CTRL) was analysed through LC-MS/MS, by an untargeted lipidomic approach. Receiver operating characteristic (ROC) curve and simple linear regression analyses were performed for diagnostic use. We searched for simultaneously altered lipids in plasma and CSF of MA patients.

resultsOverall, we observed a significant increase of sphingolipids (p < 0.05) and phospholipids (p < 0.05) in MA CSF. A partial least squares discriminant analysis clearly separated MA and CTRL by 64% on Principal Component 1. We identified lipid classes (n = 12) with a Variance Importance in Projection score ≥ 1.5, within those lipids highly correlated with MA (n = 70). A significant increase in acylcarnitines, sphingolipids (sphingomyelins and ceramides), phospholipids (lysophosphatidylcholines; phosphatidylcholines; phosphatidylethanolamines; ether-phosphatidylethanolamines; ether-phosphatidylcholines) and cholesterol esters was found by multivariate and univariate analyses. Monoacylglycerols were the only lipid class displaying a markedly significant (p < 0.001) decrease in CSF of MA patients as compared to CTRL subjects. The ROC curve and simple linear regression analysis identified 10 out of 12 lipid classes as reliable MA biomarkers, mainly dealing with phospholipids. We then compared current and previous data on plasma lipidomic profile. The discriminant analysis returned n = 175 (in plasma) and n = 70 (in CSF) simultaneously altered lipids respectively, and phosphatidylcholines (n = 10) resulted as commonly decreased in plasma and increased in CSF.

conclusionsOur findings highlighted a strong pro-inflammatory environment in MA CSF. These preliminary hallmarks could be helpful to decipher the complex MA pathogenesis, by supplying candidate biomarkers for patient stratification.

Indexed as

LipidomicsLipidsMoyamoya DiseaseAdolescentAdultBiomarkersChildFemaleHumansMaleMiddle AgedPhospholipidsYoung AdultBiomarkersLipidsPhospholipidsCSFInflammationLipidomicsMoyamoyaPhosphatidylcholinesPhospholipidsPlasmaSphingolipids

Identifiers

PMID40410905
PMCPMC12101001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.